SCHEMBL4223501

SCHEMBL4223501

CC(C)(C)OC(=O)c1ccc(-c2ccc(NS(C)(=O)=O)cc2)cc1Nc1ccc2c(c1)OCO2

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.50
PIK3CD O00329 1/20 0.46
KIF11 P52732 1/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
PKM P14618 1/20 0.44
NPC1 O15118 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
MAPT P10636 2/20 0.39
TSHR P16473 1/20 0.39
IDH1 O75874 1/20 0.38
GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227637 0.86 RAB9A (0.56) RAB9APIK3CDKIF11KMT2AMEN1
SCHEMBL4223945 0.83 MAPT (0.47) RAB9AKMT2AMEN1PKMNPC1
SCHEMBL4215672 0.82 NPC1 (0.43) RAB9AKMT2AMEN1PKMNPC1
SCHEMBL4221468 0.80 RAB9A (0.41) RAB9AKMT2AMEN1PKMNPC1
SCHEMBL4215697 0.78 CA2 (0.41) PIK3CDKIF11KMT2AALDH1A1KDM4E
SCHEMBL4212804 0.78 HPGD (0.43) KIF11ALDH1A1HPGDGPR119
SCHEMBL4215853 0.76 RAB9A (0.49) RAB9AKMT2AMEN1NPC1SMN1; SMN2
SCHEMBL4215669 0.74 KIF11 (0.46) KIF11HPGDGPR119
SCHEMBL4217099 0.73 ABCG2 (0.46) ALDH1A1KDM4EMAPT
SCHEMBL13890999 0.73 FABP3 (0.44) RAB9AKMT2ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 RAB9A 2262/4885PIK3CD 4424/4885KIF11 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.